University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Thomas G. Martin III

Thomas G. Martin III, M.D.

Blood disorder specialist

A leading expert in hematology-oncology, Dr. Thomas Martin is the associate director of the Myeloma Program and director of the Unrelated Donor Transplantation Programs for adults at UCSF Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes following unrelated donor transplants.

Martin earned an undergraduate degree at Cornell University and a medical degree at the University of Connecticut School of Medicine in Farmington, Conn. After a medical residency at Harbor-UCLA Medical Center in Torrance, Calif., He completed fellowships in hematology-oncology at UCSF, where he was promoted to an adjunct professor of medicine, division of hematology and oncology. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine. In 2001, he rejoined the faculty at UCSF, where he is a clinical professor of medicine.

Conditions & Treatments

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

More about Thomas G. Martin III

Additional Languages

Spanish

Education

University of Connecticut, School of Medicine 1989

Residencies

Harbor-UCLA Medical Center, Internal Medicine 1992

Fellowships

UCSF Hematology/Oncology Division, Hematology/Oncology 1996

Selected Research and Publications

  1. Wei R, Martin TG, Rant U, Dietz H. DNA origami gatekeepers for solid-state nanopores. Angew Chem Int Ed Engl. 2012 May 14; 51(20):4864-7.
  2. Martin TG, Clarke DR, Bowrey DJ. Medical students in theatre: Setting the scene. Med Teach. 2012; 34(4):337.
  3. Martin TG, Smyth JA. The ability of disease and non-disease producing strains of Clostridium perfringens from chickens to adhere to extracellular matrix molecules and Caco-2 cells. Anaerobe. 2010 Oct; 16(5):533-9.
  4. Smyth JA, Martin TG. Disease producing capability of netB positive isolates of C. perfringens recovered from normal chickens and a cow, and netB positive and negative isolates from chickens with necrotic enteritis. Vet Microbiol. 2010 Nov 20; 146(1-2):76-84.
  5. Martin TG, Smyth JA. Prevalence of netB among some clinical isolates of Clostridium perfringens from animals in the United States. Vet Microbiol. 2009 Apr 14; 136(1-2):202-5.
  6. Martin TG, Iannotti JP. Reverse total shoulder arthroplasty for acute fractures and failed management after proximal humeral fractures. Orthop Clin North Am. 2008 Oct; 39(4):451-7, vi.
  7. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.
  8. Seifert SA, Keyler D, Isbister G, McNally J, Martin TG. ACMT Position Statement: Institutions housing venomous animals. J Med Toxicol. 2006 Sep; 2(3):118-9.
  9. Paredes VL, Rea TD, Eisenberg MS, Cobb LA, Copass MK, Cagle A, Martin TG. Out-of-hospital care of critical drug overdoses involving cardiac arrest. Acad Emerg Med. 2004 Jan; 11(1):71-4.
  10. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002 Sep; 58(3):560-8.
  11. Martin TG, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):121-43.
  12. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am. 2001 Feb; 15(1):97-120.
  13. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2.
  14. Roberge RJ, Martin TG. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994 Mar; 23(3):586-90.
  15. Martin TG, Hawkins NS, Weigel JA, Rider DE, Buckingham BD. Initial treatment of ventricular fibrillation: defibrillation or drug therapy. Am J Emerg Med. 1988 Mar; 6(2):113-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California